Spyre Therapeutics, Inc. SYRE Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $60.41M+45.1% | $44.64M-11.6% | $45.25M+1.1% | $40.15M+23.0% | $41.62M+19.2% | ||
| $15.23M+27.5% | $12.53M+16.4% | $11.64M+9.3% | $11.79M+2.4% | $11.94M-7.0% | ||
| $45.64M-14.8% | $57.17M-6.7% | $56.89M+2.7% | $41.94M-5.0% | $53.57M+12.1% | ||
| -$45.64M+14.8% | -$57.17M+6.7% | -$56.89M-2.7% | -$41.94M+5.0% | -$53.57M-12.1% | ||
| -$23.36M-366% | $0-100% | $45.71M+436% | $5.22M-1.7% | $8.78M+122% | ||
| -$69.01M-54.1% | -$62.53M-11.1% | -$11.18M+83.8% | -$36.72M+5.5% | -$44.79M-2.2% | ||
| $0+100% | $0-100% | $0-100% | $0— | -$15K-147% | ||
| -$69.01M-54.1% | -$62.53M-11.1% | -$11.18M+83.8% | -$36.72M+5.5% | -$44.77M-2.1% | ||
| -$0.74-23.3% | -$0.74-208% | -$0.15+89.0% | -$0.49+43.0% | -$0.60+16.7% | ||
| -$45.64M+14.8% | -$57.17M+6.7% | -$56.89M-2.7% | -$41.94M+5.0% | -$53.57M-12.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Spyre Therapeutics, Inc. profitable?
- Spyre Therapeutics, Inc. is not currently profitable: it reported a net loss of $179.4M over the trailing twelve months, a -52939.7% net margin.
- What is Spyre Therapeutics, Inc.'s earnings per share?
- Spyre Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-2.12.
- Where does Spyre Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.